WO2014115084A3 - Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof - Google Patents

Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof Download PDF

Info

Publication number
WO2014115084A3
WO2014115084A3 PCT/IB2014/058461 IB2014058461W WO2014115084A3 WO 2014115084 A3 WO2014115084 A3 WO 2014115084A3 IB 2014058461 W IB2014058461 W IB 2014058461W WO 2014115084 A3 WO2014115084 A3 WO 2014115084A3
Authority
WO
WIPO (PCT)
Prior art keywords
enzymes
recombinant human
ponl
present
provides
Prior art date
Application number
PCT/IB2014/058461
Other languages
French (fr)
Other versions
WO2014115084A2 (en
Inventor
Abhay Hariram PANDE
Priyanka BAJAJ
Rajan Kumar TRIPATHY
Geetika Agrawal
Original Assignee
National Institute Of Pharmaceutical Education And Research (Niper)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Pharmaceutical Education And Research (Niper) filed Critical National Institute Of Pharmaceutical Education And Research (Niper)
Publication of WO2014115084A2 publication Critical patent/WO2014115084A2/en
Publication of WO2014115084A3 publication Critical patent/WO2014115084A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/08—Phosphoric triester hydrolases (3.1.8)
    • C12Y301/08001—Aryldialkylphosphatase (3.1.8.1), i.e. paraoxonase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01002—Arylesterase (3.1.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides novel polynucleotide sequences for high level expression in Escherichia coli and encoding recombinant human paraoxonase 1 enzymes having enhanced hydrolytic activity towards at least one PONl -substrates. The invention also provides a novel method to produce the recombinant enzymes in highly pure and active form in an unprecedented high yield. The invention also provides novel compositions for long-term storage stability of purified enzymes under various storage conditions. The molecules disclosed in the present invention can be used as therapeutic protein against PONl -associated disease conditions as well as agent for decontamination of OP-contaminated areas and objects.
PCT/IB2014/058461 2013-01-28 2014-01-22 Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof WO2014115084A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN0228/DEL/2013 2013-01-28
IN228/DEL/2013A IN2013DE00228A (en) 2013-01-28 2013-01-28 “recombinant human paraoxonase 1 enzymes, method of generation and uses thereof”

Publications (2)

Publication Number Publication Date
WO2014115084A2 WO2014115084A2 (en) 2014-07-31
WO2014115084A3 true WO2014115084A3 (en) 2014-11-20

Family

ID=51228148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058461 WO2014115084A2 (en) 2013-01-28 2014-01-22 Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof

Country Status (2)

Country Link
IN (1) IN2013DE00228A (en)
WO (1) WO2014115084A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110387380B (en) * 2019-07-09 2021-05-04 武汉华肽生物科技有限公司 Production method of gene recombinant protein Tat-hMsrA
CN113621686A (en) * 2021-08-11 2021-11-09 海南微氪生物科技股份有限公司 Detection method suitable for various pathogenic microorganisms
CN114609216B (en) * 2022-03-25 2024-03-19 内江师范学院 beta-CD modified electrode, preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028924A1 (en) * 2006-03-16 2010-02-04 Rappaport Family Institute Research in the Medical Sciences Method Of Diagnosing Pon1-Hdl Associated Lipid Disorders
US20120213834A1 (en) * 2009-09-17 2012-08-23 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028924A1 (en) * 2006-03-16 2010-02-04 Rappaport Family Institute Research in the Medical Sciences Method Of Diagnosing Pon1-Hdl Associated Lipid Disorders
US20120213834A1 (en) * 2009-09-17 2012-08-23 Yeda Research And Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU, HAIQIN ET AL.: "Cloning, purification, and refolding of human paraoxonase-3 expressed in Escherichia coli and its characterization", PROTEIN EXPRESSION AND PURIFICATION, vol. 46, no. 1, 2006, pages 92 - 99 *

Also Published As

Publication number Publication date
WO2014115084A2 (en) 2014-07-31
IN2013DE00228A (en) 2015-06-19

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
SG10201906859PA (en) Novel proteins specific for angiogenesis
EP2493507A4 (en) Ax213 and ax132 pcsk9 antagonists and variants
MX2016002934A (en) Antisense-induced exon2 inclusion in acid alpha-glucosidase.
BR112016002753A2 (en) antibodies to plasminogen activator inhibitor-1 (parent-1) and uses thereof
MX2017011004A (en) Antisense-induced exon2 inclusion in acid alpha-glucosidase.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
PH12017501118B1 (en) Pharmaceutical composition comprising plasminogen and uses thereof
MX363936B (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c.
BR112012033404A2 (en) polypeptide having or assisting the degradation activity of carbohydrate material and use thereof.
TN2013000427A1 (en) Modified acid alpha glucosidase with accelerated processing
MX2013012661A (en) Bicyclic pyridazine compounds as pim inhibitors.
SG10201804952QA (en) Glucosylceramide synthase inhibitors
EA201171043A1 (en) COMPOSITIONS AND METHODS OF LONG-TERM THERAPY WITH THE USE OF AMINOPYRIDINES
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
BR112013001753A2 (en) a method for preparing a plasma erected alpha-inhibitor (aiip) composition, aqueous iaip solution, and a method for treating a disease or disorder associated with iaip dysfunction and associated with increased plasma serine protease activity.
MX2014010664A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use.
PH12016502100A1 (en) Liquid formulation comprising gm-csf neutralizing compound
EA201790178A1 (en) PEPTIDES BEARING MANNOSE-6-PHOSPHATE, FUSED WITH LIZOSOMAL ENZYME
IN2014DN06920A (en)
PH12015502021A1 (en) Salt forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
GB201206486D0 (en) Vesicular formulations and uses thereof
MX2016000480A (en) High potency pancreatin pharmaceutical compositions.
WO2012064709A3 (en) Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
MX2018010196A (en) Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14743847

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14743847

Country of ref document: EP

Kind code of ref document: A2